US5437861A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1993-03-16
•
Granted: 1995-08-01
•
Expires: 2013-03-16
Abstract
Abstract This invention provides a composition, device and method for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood.
Inventors
- 👤 Thomas B. Okarma
- 👤 John Blankenship
- 👤 Abraham T. Lin
- 👤 Mohammad A. Elkalay
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 01:03
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61M1/34; A61M1/342; A61M1/3424; A61M1/3431; A61M1/3621; A61M1/3643; A61M1/3644; A61M1/3672; A61M1/3673; Y; Y10; Y10S; Y10S530/00; Y10S530/81; Y10S530/811
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
78 words
A composition of matter comprising amorphous, particulate, non-spherical silica and a silica pretreating agent wherein the silica pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area between 150 m 2 /g and 600 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin; and wherein the composition is capable of removing selected factors from blood.
Claim 2
Dependent Claim
78 words
A composition of matter comprising amorphous, particulate, non-spherical silica and a silica pretreating agent wherein the silica pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area between 150 m 2 /g and 600 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, and wherein the silica pretreating agent is heparin or albumin; and wherein the composition is capable of removing selected factors from blood.
Claim 3
Dependent Claim
24 words
The composition of claim 1 wherein the specific surface area of the silica is between 150 m 2 /g and 1000 m 2 /g.
Claim 4
Dependent Claim
24 words
The composition of claim 2, wherein the specific surface area of the silica is between 200 m 2 /g and 600 m 2 /g.
Claim 5
Dependent Claim
18 words
The composition of claim 1 wherein the porosity of the silica is between 0.8 cc/g and 1.5 cc/g.
Claim 6
Dependent Claim
12 words
The composition of claim 1 wherein the silica is substantially unmodified chemically.
Claim 7
Dependent Claim
19 words
The composition of claim 1 in which the silica particles have a mean diameter less than about 1 mm.
Claim 8
Dependent Claim
20 words
The composition of claim 1 in which the silica particles have a mean diameter between about 50 and 250 microns.
Claim 9
Dependent Claim
21 words
The composition of claim 1 in which the silica has a mean pore diameter of about 30 Å to 300 Å.
Claim 10
Dependent Claim
21 words
The composition of claim 8 in which the silica has a mean pore diameter of about 60 Å to 200 Å.
Claim 11
Dependent Claim
23 words
The composition of claim 1 in which the human serum albumin comprises between 1% and 25% by weight of the silica pretreating agent.
Claim 12
Dependent Claim
21 words
The composition of claim 10 in which the human serum albumin comprises between 2.5% and 5% of the silica pretreating agent.
Claim 13
Dependent Claim
21 words
The composition of claim 1 in which the selected factors comprise cytokines, complement molecules, serotonin, histamine, cholesterol molecules, or angiogenesis factor.
Claim 14
Dependent Claim
28 words
The composition of claim 1, wherein the composition is comprised within a porous solid matrix, and wherein the composition is substantially devoid of covalent attachment to the matrix.
Claim 15
Dependent Claim
18 words
The composition of claim 1 contained within an article, the article comprising a means for retaining the composition.
References Cited (Backward Citations)
US3607857A
Cited
US4059685A
Cited
US4006059A
Cited
US3998946A
Cited
US4102746A
Cited
GB1536425A
Cited
US4072566A
Cited
DE3109123A1
Cited
US4787974A
Cited
US4420395A
Cited
US4472303A
Cited
US4728432A
Cited
US4861870A
Cited
US4748121A
Cited
US4883765A
Cited
WO1988009202A1
Cited
US4865841A
Cited
US5041079A
Cited
US4963265A
Cited
US5022988A
Cited
WO1990000903A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-07-31 | 1999-01-30 | 1999-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-07-31 | 2003-01-30 | 2003-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-07-31 | 2007-01-30 | 2007-08-01 | $7700.00 | Window Closed / Lapsed |